Tag: biOasis Technologies
July 16, 2018
Bioasis Announces Non-Brokered Private Placement
Bioasis Technologies (TSXV:BTI) has announced its intentions to pursue a non-brokered private placement of units at $0.552 per unit for... July 11, 2018
Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic
BIOASIS TECHNOLOGIES (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain... June 14, 2017
CEO of biOasis Technologies Gives Update to Shareholders
The CEO of biOasis Technologies issued a message to shareholders for the advancement of the Transcend Platform and the company's... April 25, 2017
biOasis Technologies Appoints New CEO
biOasis Technologies announced the appointment of Dr. Mark Day as president and CEO of the company.
April 13, 2017